Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer
At the end of 1976 and the beginning of 1977 respectively, the EORTC Genito-Urinary Tract Cancer Cooperative Group started two randomized phase III protocols in previously untreated patients with advanced T3–4 prostatic cancer (1–3). The first trial, 30762, compared Stilboestrol and Estracyt, while the second, 30761, was a randomized comparison of Stilboestrol, Cyproterone Acetate and Medroxyprogesterone Acetate. Both trials have now been closed to patient entry and the principal endpoints of the studies analyzed. This paper will present the interim results which have emerged from these two studies.
KeywordsBone Metastasis Cardiovascular Death Prostatic Tumour Medroxyprogesterone Acetate Cyproterone Acetate
Unable to display preview. Download preview PDF.
- 1.M. Pavone-Macaluso, F. Lund, J.H. Mulder, P.H. Smith, M. de Pauw, R. Sylvester, and EORTC Urological Group, EORTC Protocols in Prostatic Cancer, An Interim Report, Scand. J. Urol. Nephrol. Suppl. 55: 163 (1980).Google Scholar
- 2.P.H. Smith, A. Akdas, M.K. Mason, B. Richards, M. Robinson, M. de Pauw, and R. Sylvester, Hormone therapy in prostatic cancer, Acta. Urol. Belg. 48: 282 (1980).Google Scholar